Maartje J L Colaris1, Tim Ruhl2, Justus P Beier2. 1. Department of Plastic Surgery, Hand Surgery-Burn Center, University Hospital RWTH Aachen, Pauwelsstraße 30, 52074, Aachen, Germany. mcolaris@ukaachen.de. 2. Department of Plastic Surgery, Hand Surgery-Burn Center, University Hospital RWTH Aachen, Pauwelsstraße 30, 52074, Aachen, Germany.
Abstract
BACKGROUND: Silicone (gel) breast implants (SBI) are used world-wide for breast augmentation, and reconstruction or to correct breast deformities. They consist of two compounds: an elastomer silicone shell (envelope) and a silicone gel filler (core). Breast Implant Illness (BII) is a term used for women with SBI, who suffer from various of symptoms including myalgia, arthralgia, fatigue, fever, dry eyes and/or dry mouth (sicca), as well as cognitive disturbances, which are rated by these woman as response to SBI. The pathogenesis of these adverse effects as well as the histocompatibility and the SBI-cell interaction of silicone and its surrounding tissue (implant-host tissue interface) is a subject of current research. The main purpose of this review is to provide an overview of the current knowledge regarding the effects of silicone (gel and elastomer surfaces) of a SBI on different human cell types from experimental - in vitro - models. METHODS: A comprehensive research was conducted by two independent reviewers in March and July of 2020 in the PubMed, MEDLINE, and Cochrane databases. RESULTS: A number of 1328 articles on this topic were initially identified, of which 62 could be finally included an analysed in this review. CONCLUSION: SBI may lead to a physiologic pro-inflammatory and foreign body host response with fibrous encapsulation accompanied by a disturbed Th17/Treg balance and IL-17 production. No causal relationship is known for systemic symptoms and/or autoimmune outcomes in the context of BII. LEVEL OF EVIDENCE III: This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266 .
BACKGROUND: Silicone (gel) breast implants (SBI) are used world-wide for breast augmentation, and reconstruction or to correct breast deformities. They consist of two compounds: an elastomer silicone shell (envelope) and a silicone gel filler (core). Breast Implant Illness (BII) is a term used for women with SBI, who suffer from various of symptoms including myalgia, arthralgia, fatigue, fever, dry eyes and/or dry mouth (sicca), as well as cognitive disturbances, which are rated by these woman as response to SBI. The pathogenesis of these adverse effects as well as the histocompatibility and the SBI-cell interaction of silicone and its surrounding tissue (implant-host tissue interface) is a subject of current research. The main purpose of this review is to provide an overview of the current knowledge regarding the effects of silicone (gel and elastomer surfaces) of a SBI on different human cell types from experimental - in vitro - models. METHODS: A comprehensive research was conducted by two independent reviewers in March and July of 2020 in the PubMed, MEDLINE, and Cochrane databases. RESULTS: A number of 1328 articles on this topic were initially identified, of which 62 could be finally included an analysed in this review. CONCLUSION: SBI may lead to a physiologic pro-inflammatory and foreign body host response with fibrous encapsulation accompanied by a disturbed Th17/Treg balance and IL-17 production. No causal relationship is known for systemic symptoms and/or autoimmune outcomes in the context of BII. LEVEL OF EVIDENCE III: This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266 .
Authors: Abdulla Watad; Vered Rosenberg; Shmuel Tiosano; Jan Willem Cohen Tervaert; Yarden Yavne; Yehuda Shoenfeld; Varda Shalev; Gabriel Chodick; Howard Amital Journal: Int J Epidemiol Date: 2018-12-01 Impact factor: 7.196
Authors: Alexander D Bach; Ulrich Kneser; Justus P Beier; Christiane Breuel; Raymund E Horch; Mareike Leffler Journal: Breast J Date: 2009 May-Jun Impact factor: 2.431
Authors: Christopher J Coroneos; Jesse C Selber; Anaeze C Offodile; Charles E Butler; Mark W Clemens Journal: Ann Surg Date: 2019-01 Impact factor: 12.969
Authors: Mintsje de Boer; Flora E van Leeuwen; Michael Hauptmann; Lucy I H Overbeek; Jan Paul de Boer; Nathalie J Hijmering; Arthur Sernee; Caroline A H Klazen; Marc B I Lobbes; René R W J van der Hulst; Hinne A Rakhorst; Daphne de Jong Journal: JAMA Oncol Date: 2018-03-01 Impact factor: 31.777
Authors: Mintsje de Boer; Michele van Middelkoop; Michael Hauptmann; Noortje van der Bijl; Jorn A W Bosmans; Narda Hendriks-Brouwer; Sijmen J Schop; Jan Paul de Boer; Nathalie J Hijmering; Lucy I H Overbeek; Marc B I Lobbes; Caroline A H Klazen; Daphne de Jong; Hinne A Rakhorst; René R W J van der Hulst; Flora E van Leeuwen Journal: Aesthet Surg J Date: 2020-01-29 Impact factor: 4.283